Abgenix, Inc. (ABGX) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (275)	10/17/2003 8:54:12 AM
From: nigel bates	Read Replies (1) of 590

Instead they seem to be on their way to become a mAb-based super CRO providing all the services needed to convert a target into a mAb-based biological agent. Not exactly. They get milestone & royalties, in addition to commercial rates for their manufacturing and CRO activities. And don't forget this is just oncology - leaves quite a few other indications... And that it was not enough to know how to create fully human antibodies to be successful in drug development... Agreed. But now they get to learn at someone else's expense. It's also sensible (necessary ?) insurance against failure of ABX-EGF. At the current market cap, they're just not going to be as exciting as some of the stuff we dabble in, anyway. To me, this is a good deal (FWIW).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next